Trial · NCT00479882
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Precrossover: Periods I/II (Weeks 1-12) | STARTED | Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg | 610 | |
| Precrossover: Periods I/II (Weeks 1-12) | STARTED | Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg | 602 | |
| Precrossover: Periods I/II (Weeks 1-12) | STARTED | Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg | 597 | |
| Precrossover: Periods I/II (Weeks 1-12) | STARTED | Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg | 605 | |
| Precrossover: Periods I/II (Weeks 1-12) | COMPLETED | Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg | 472 | |
| Precrossover: Periods I/II (Weeks 1-12) | COMPLETED | Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg | 440 | |
| Precrossover: Periods I/II (Weeks 1-12) | COMPLETED | Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg | 440 | |
| Precrossover: Periods I/II (Weeks 1-12) | COMPLETED | Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg | 465 | |
| Precrossover: Periods I/II (Weeks 1-12) | NOT COMPLETED | Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg | 138 | |
| Precrossover: Periods I/II (Weeks 1-12) | NOT COMPLETED | Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg | 162 | |
| Precrossover: Periods I/II (Weeks 1-12) | NOT COMPLETED | Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg | 157 | |
| Precrossover: Periods I/II (Weeks 1-12) | NOT COMPLETED | Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg | 140 | |
| Crossover: Period III (Weeks 13-20) | STARTED | Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg | 472 | |
| Crossover: Period III (Weeks 13-20) | STARTED | Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg | 440 | |
| Crossover: Period III (Weeks 13-20) | STARTED | Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg | 440 | |
| Crossover: Period III (Weeks 13-20) | STARTED | Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg | 465 | |
| Crossover: Period III (Weeks 13-20) | COMPLETED | Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg | 447 | |
| Crossover: Period III (Weeks 13-20) | COMPLETED | Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg | 419 | |
| Crossover: Period III (Weeks 13-20) | COMPLETED | Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg | 420 | |
| Crossover: Period III (Weeks 13-20) | COMPLETED | Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg | 447 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00479882/flow